A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland
Barbier M, Pardo E, Panje C, Gautschi O, Lupatsch J, Swiss Group for Clinical Cancer Research (SAKK). A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland. Eur J Health Econ 2021; 22:669-677.
Mar 21, 2021
A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland
Mar 21, 2021
Eur J Health Econ 2021; 22:669-677
Barbier Michaela Carla, Pardo Esther, Panje Cédric, Gautschi Oliver, Lupatsch Judith Eva, Swiss Group for Clinical Cancer Research (SAKK)
more
